Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – What’s Next?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $8.91, but opened at $8.29. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.51, with a volume of 7,693 shares traded.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The stock’s 50 day moving average is $9.89 and its two-hundred day moving average is $9.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The stock has a market capitalization of $14.70 billion, a PE ratio of 10.80, a price-to-earnings-growth ratio of 3.42 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The firm had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. As a group, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.